Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for ...

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory ...

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...

Novo Nordisk late Thursday announced that it will advance subcutaneous (SC) and oral amycretin into Phase III development in ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Find insight on Malaysia’s glove sector, Novo Nordisk and more in the latest Market Talks covering the Health Care sector.

Oracle Corp. (ORCL) shares jumped 13.3% after reporting fourth-quarter fiscal 2025 adjusted earnings per share of $1.70, surpassing the Zacks Consensus Estimate of $1.64. Shares of Alphabet Inc.

COPENHAGEN] Novo Nordisk reclaimed its position as Europe’s most valuable public company, overtaking software developer SAP. Read more at The Business Times.

The FTSE 100 and European stocks dropped and oil prices spiked on Friday, as traders react to a major escalation in tensions between Iran and Israel overnight. Israel's military s ...